Modulation of CD3-zeta as a marker of clinical response to IL-2 therapy in ovarian cancer patients

Gynecologic Oncology

Volumn 94, Issue 1, 2004, Pages 54-60

  Taylor, Douglas D ^a   Edwards, Robert P ^a   Case, Catherine R ^a   Gerçel Taylor, Çiçek ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

IL 2; Jurkat cells; Zeta expression

Indexed keywords

BIOLOGICAL MARKER; CD3 ANTIGEN; RECOMBINANT CYTOKINE; RECOMBINANT INTERLEUKIN 2;

ADVANCED CANCER; ANTIGEN EXPRESSION; ARTICLE; BLOOD ANALYSIS; CANCER PATIENT; CELL ASSAY; CHROMATOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DRUG RESPONSE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOTHERAPY; LEUKEMIA CELL LINE; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REGULATORY MECHANISM; WESTERN BLOTTING;

ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; ENVIRONMENTAL MONITORING; FEMALE; HUMANS; INTERLEUKIN-2; JURKAT CELLS; OVARIAN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 3242692590     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.03.032     Document Type: Article

References (31)

1. Berek JS. Epithelial ovarian cancer. In: Berek JS, Hacker NF, editors. Practical gynecologic oncology. third ed. Lippincott William & Wilkins; 2000.
2. Cannistra SA. Cancer of the ovary. N Engl J Med 1993;329:1550.
3. Thigpen JT, Vance RB, Khansur T. Second-line chemotherapy for recurrent carcinoma of the ovary. Cancer 1992;71:1559-64.
4. Lai P, Rabinowich H, Crowley-Nowick PA, Bell MC, Mantovani G, Whiteside TL. Alterations in expression and function of signal-transducing proteins in tumor-associated T and natural killer cells in patients with ovarian carcinoma. Clin Cancer Res 1996;2:161-73.
5. Rabinowich H, Suminami Y, Reichert TE, Crowley-Nowick P, Bell M, Edwards R, et al. Expression of cytokine genes or proteins and signaling molecules in lymphocytes associated with human ovarian carcinoma. Int J Cancer 1996;68:276-84.
6. Whiteside TL. Signaling defects in T lymphocytes of patients with malignancy. Cancer Immunol Immunother 1999;48:346-52.
7. Reichert TE, Rabinowich H, Johnson JT, Whiteside TL. Immune cells in the tumor microenvironment: mechanisms responsible for signaling and functional defects. J Immunother 1998;21:295-306.
8. Maccalli C, Pisarra P, Vegetti C, Sensi M, Parmiani G, Anichini A. Differentiation loss of T cell signaling molecules in metastatic melanoma patients' T lymphocyte subsets expressing distinct TCR variable regions. J Immunol 1999;163:6912-23.
9. Reichert TE, Strauss L, Wagner EM, Gooding W, Whiteside TL. Signaling abnormalities, apoptosis, reduced proliferation of circulating and tumor-infiltrating lymphocytes in patients with oral carcinoma. Clin Cancer Res 2002;8:3137-45.
10. Reichert TE, Day R, Wagner EM, Whiteside TL. Absent or low expression of the ζ chain in T cells at the tumor site correlates with poor survival in patients with oral carcinoma. Cancer Res 1998;58:5344-7.
11. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Higashi H, Iwashige H, et al. CD3-zeta chain expression of intratumoral lymphocytes is closely related to survival in gastric carcinoma patients. Cancer 2002;94:1437-42.
12. Rabinowich H, Reichert TE, Kashii Y, Bell MC, Whiteside TL. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of TcR in tumor-associated lymphocytes. J Clin Invest 1998;101:2579-88.
13. Schmielau J, Nalesnik MA, Finn OJ. Suppressed T-cell receptor z chain expression and cytokine production in pancreatic cancer patients. Clin Cancer Res 2001;7:933s-9s.
14. von Bernstorff W, Voss M, Frieichel S, Schmid A, Vogel I, Jöhnk C, et al. Systemic and local immunosuppression in pancreatic cancer patients. Clin Cancer Res 2001;7:925s-32s.
15. Gastman BR, Atarashi Y, Reichert TE, Saito T, Balkir L, Rabinowich H, et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck and it promotes apoptosis of T lymphocytes. Cancer Res 1999;59:5356-64.
16. + peripheral blood T lymphocytes of patients with melanoma. Clin Cancer Res 2001;7:947s-57s.
17. Walpole ET, Dutcher JP, Sparano J, Gucalp R, Einzig A, Paietta E, et al. Survival after phase II treatment of advanced renal cell carcinoma with Taxol or high dose interleukin-2. J Immunother 1993;13:275-81.
18. Edwards RP, Gooding W, Lembersky BC, Colonello K, Hammond R, Paradise C, et al. Comparison of toxicity and survival following intraperitoneal recombinant interleukin-2 for persistent ovarian cancer after platinum: twenty-four-hour versus 7-day infusion. J Clin Oncol 1997;15:3399-407.
19. Weiss A, Littman DR. Signal transduction by lymphocyte antigen receptors. Cell 1994;76:263-74.
20. Johansson B, Palmer E, Bolliger L. The extracellular domain of the zeta-chain is essential for TCR function. J Immunol 1999;162:878-85.
21. Kuss I, Rabinowich H, Gooding W, Edwards R, Whiteside TL. Expression of zeta in T cells prior to interleukin-2 therapy as a predictor of response and survival in patients with ovarian carcinoma. Cancer Biother Radiopharm 2002;17:631-40.
22. Rabinowich H, Banks M, Reichert T, Logan TF, Kirkwood JM, Whiteside TL. Expression and activity of signaling molecules in T lymphocytes obtained from patients with metastatic melanoma before and after interleukin-2 therapy. Clin Cancer Res 1996;2:1263-72.
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (Lond.) 1970;227:680-5.
24. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, et al. Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 1993;55:678-84.
25. Mizoguchi H, O'Shea JJ, Longo DL, Loeffler CM, McVicar DW, Ochoa AC. Alterations in signal transduction molecules in T lymphocytes from tumor-bearing mice. Science 1992;258:1795-8.
26. Zea AH, Brendan CD, Longo DL, Alvord WG, Strobl SL, Mizoguchi H, et al. Alterations in T cell receptor and signal transduction molecules in melanoma patients. Clin Cancer Res 1995;1:1327-35.
27. Taylor DD, Bender DP, Gerçel-Taylor C, Stanson J, Whiteside TL. Modulation of TcR/CD3-zeta chain expression by a circulating factor derived from ovarian cancer patients. Br J Cancer 2001;84:1624-9.
28. Healy CG, Simons JW, Carducci MA, DeWeese TL, Bartkowski M, Tong KP, et al. Impaired expression and function of signal-transducing zeta chains in peripheral T cells and natural killer cells in patients with prostate cancer. Cytometry 1998;32:109-19.
29. Kolenko V, Wang Q, Riedy MC, O'Shea J, Ritz J, Cathcart MK, et al. Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling. Role of soluble products from human renal cell carcinomas. J Immunol 1997;159:3057-67.
30. Horiguchi S, Petersson M, Nakazawa T, Kanda M, Zea AH, Ochoa AC, et al. Primary chemically induced tumors induce profound immunosupression concomitant with apoptosis and alterations in signal transduction in T cells and NK cells. Cancer Res 1999;59:2950-6.
31. Kono K, Ressing ME, Brandt RMP, Melief CJM, Potkul RK, Andersson B, et al. Decreased expression of signal-transducing ζ chain in peripheral T cells and natural killer cells in patients with cervical cancer. Clin Cancer Res 1996;2:1825-8.